Cell Pathways Aptosyn
Executive Summary
NDA submitted Aug. 26 for exisulind for the treatment of adenomatous polyposis coli, a condition that can lead to colon cancer. The orphan drug, previously known as Prevatac, has been given fast track status and will undergo priority review. The company hopes to submit further data on clinical trials to FDA within 90 days